So long as COVID-19 continues to pose a high risk to patients in the absence of an effective treatment or vaccine, it is crucial to collect large amounts of high-quality data on this virus. Harmonization of data is needed in order to facilitate the rapid analysis of COVID-19 characteristics and support evidence-based decision making in clinical practice. COVID-19 data are currently fragmented and siloed across poorly interoperable systems. Therefore, a substantial level of curation is required to ensure data are relevant and of high quality.
The HARMONY Alliance, in close collaboration with the European Hematology Association (EHA), is organizing a webinar about 'the power of integrating harmonized COVID-19 patient data in hematology research'.
Date: June 4, 2020 | Time: 17:00 - 18:00 CEST
Clinicians and hematologists are invited to join; participation is free of charge. Simply click this link to watch the webinar: HARMONY-EHA webinar - direct YouTube link
To those of you who have registered for the event, you will be redirected to the YouTube link above because registration is no longer required in order to attend.
Learn about the added value of harmonized clinical data, Big Data analytics tools and the HARMONY approach.
Webinar topics and speakers
HARMONY in COVID-19 pandemic: the power of Big Data to address emerging needs
HARMONY’s Case Report Form (CRF) for COVID-19 in patients with Hematologic Malignancies
European study on Myeloproliferative neoplasms and COVID-19: a HARMONY Research Project
Moderator
The HARMONY Alliance is a public-private partnership for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders. The ultimate goal of HARMONY is to harness and mine Big Data to speed up the development of improved treatments and treatment strategies for patients.
We currently have 53 Partners and 41 Associated Members from across 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI).
HARMONY takes action to manage COVID-19
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
